Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 0.39 |
| ▸ | HTR7 | P34969 | 6/20 | 0.39 |
| ▸ | DRD2 | P14416 | 6/20 | 0.39 |
| ▸ | HTR1A | P08908 | 5/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1815031 | 0.82 | DRD2 (0.46) | DRD2ADRA1AHTR6DRD3ALDH1A1 | |
| SCHEMBL16462683 | 0.80 | GAA (0.53) | HTR7DRD2HTR6DRD3ALDH1A1 | |
| SCHEMBL16462696 | 0.80 | BRD1 (0.39) | HTR7ADRA1AALDH1A1ADRA1DADRA1B | |
| SCHEMBL3436274 | 0.79 | ADRA1B (0.55) | HTR2AHTR7DRD2HTR1AADRA1A | |
| SCHEMBL16462919 | 0.79 | ALDH1A1 (0.35) | HTR7ADRA1AALDH1A1ADRA1DADRA1B | |
| SCHEMBL188362 | 0.78 | ADRA2C (0.42) | HTR2ADRD2HTR1ADRD3ALDH1A1 | |
| SCHEMBL1814737 | 0.77 | DRD2 (0.47) | HTR2AHTR7DRD2HTR1AADRA1A | |
| SCHEMBL1811703 | 0.75 | OPRL1 (0.38) | DRD2 | |
| SCHEMBL27770508 | 0.75 | GAA (0.35) | HTR7HTR1AADRA1AADRA1DADRA1B | |
| SCHEMBL4575709 | 0.75 | DRD2 (0.44) | HTR2ADRD2HTR1ADRD3ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288396-B2 | Pyrimidopyrimidoindazole derivative | MSDKK (JP) | 2012-10-16 | — | — | US | disclosed |
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-05-31 | — | — | US | disclosed |
| EP-2401281-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | MSD K.K. (JP) | 2012-01-04 | — | — | EP | disclosed |
| WO-2010098367-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120134955-A1 | PYRIMIDOPYRIMIDOINDAZOLE DERIVATIVE | WEE1, WEE2, DCK | HTR2A 4687/4885HTR7 4068/4885DRD2 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.